{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:40:05Z","timestamp":1790383205477,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.bone.2020.115330","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T02:39:49Z","timestamp":1585103989000},"page":"115330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Practical guidance for the use of bisphosphonates in osteoporosis"],"prefix":"10.1016","volume":"136","author":[{"given":"Juliet","family":"Compston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7148","key":"10.1016\/j.bone.2020.115330_bb0005","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1136\/bmj.316.7148.1858","article-title":"Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group","volume":"316","author":"Micha\u00eblsson","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.bone.2020.115330_bb0010","article-title":"Long-term hormone therapy for perimenopausal and postmenopausal women","volume":"1","author":"Marjoribanks","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2020.115330_bb0015","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2020.115330_bb0020","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral Ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"5","author":"Delmas","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115330_bb0025","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. PG","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2020.115330_bb0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115330_bb0035","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115330_bb0040","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115330_bb0045","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid in reducing clinical fracture and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bone.2020.115330_bb0050","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures","volume":"164","author":"Siris","year":"2004","journal-title":"Arch. Intern. Med."},{"issue":"10","key":"10.1016\/j.bone.2020.115330_bb0055","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/jbmr.2531","article-title":"Intervention thresholds and the diagnosis of osteoporosis","volume":"30","author":"Kanis","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115330_bb0060","unstructured":"Clinician's guide to prevention and treatment of osteoporosis (National Osteoporosis Foundation Guidelines) www.natap.org\/2008\/HIV\/070708_01.htm (accessed 19\/1\/2020)."},{"issue":"1","key":"10.1016\/j.bone.2020.115330_bb0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"12","author":"Compston","year":"2017","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bone.2020.115330_bb0070","series-title":"TA464: Bisphosphonates for Treating Osteoporosis","author":"NICE","year":"2017"},{"issue":"7","key":"10.1016\/j.bone.2020.115330_bb0075","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00198-018-4505-x","article-title":"Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464)","volume":"29","author":"Harvey","year":"2018","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115330_bb0080","unstructured":"www.sheffield.ac.uk\/FRAX (accessed 19\/1\/2020)."},{"issue":"11","key":"10.1016\/j.bone.2020.115330_bb0085","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1007\/s00198-017-4160-7","article-title":"FRAX- vs. T-score-based intervention thresholds for osteoporosis","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"24","key":"10.1016\/j.bone.2020.115330_bb0090","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2020.115330_bb0095","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00198-007-0493-y","article-title":"Effects of risedronate on fracture risk in postmenopausal women with osteopenia","volume":"19","author":"Siris","year":"2008","journal-title":"Osteoporos. Int."},{"issue":"13","key":"10.1016\/j.bone.2020.115330_bb0100","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bone.2020.115330_bb0105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1359\/jbmr.061008","article-title":"Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study","volume":"22","author":"McCloskey","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2020.115330_bb0110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1359\/jbmr.070904","article-title":"Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial","volume":"23","author":"Ensrud","year":"2008","journal-title":"J. Bone Miner. Res."},{"issue":"25","key":"10.1016\/j.bone.2020.115330_bb0115","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bone.2020.115330_bb0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/joim.12901","article-title":"Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial","volume":"286","author":"Reid","year":"2019","journal-title":"J. Intern. Med."},{"issue":"8","key":"10.1016\/j.bone.2020.115330_bb0125","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jbmr.1625","article-title":"Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial","volume":"27","author":"Donaldson","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bone.2020.115330_bb0130","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00198-015-3129-7","article-title":"Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX","volume":"26","author":"Harvey","year":"2015","journal-title":"Osteoporos. Int."},{"issue":"11","key":"10.1016\/j.bone.2020.115330_bb0135","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1007\/s00198-015-3173-3","article-title":"FRAX and the effect of teriparatide on vertebral and non-vertebral fracture","volume":"26","author":"Harvey","year":"2015","journal-title":"Osteoporos. Int."},{"issue":"8","key":"10.1016\/j.bone.2020.115330_bb0140","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/jbmr.3163","article-title":"The effect of abaloparatide-SC on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study","volume":"32","author":"McCloskey","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2020.115330_bb0145","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jbmr.1606","article-title":"Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX","volume":"27","author":"McCloskey","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2020.115330_bb0150","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s00198-013-2341-6","article-title":"An evaluation of the Fracture Risk Assessment Tool (FRAX\u00ae) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX\u00ae","volume":"24","author":"Kaufman","year":"2013","journal-title":"Osteoporos. Int."},{"issue":"9","key":"10.1016\/j.bone.2020.115330_bb0155","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2020.115330_bb0160","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1359\/jbmr.081214","article-title":"Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study","volume":"24","author":"Boonen","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2020.115330_bb0165","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bone.2012.06.016","article-title":"Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study","volume":"51","author":"Boonen","year":"2012","journal-title":"Bone"},{"issue":"18","key":"10.1016\/j.bone.2020.115330_bb0170","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bone.2020.115330_bb0175","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","article-title":"Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old","volume":"52","author":"Boonen","year":"2004","journal-title":"J. Am. Geriatr. Soc."},{"issue":"6","key":"10.1016\/j.bone.2020.115330_bb0180","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1359\/JBMR.050104","article-title":"Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures","volume":"20","author":"Hochberg","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2020.115330_bb0185","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1532-5415.2009.02673.x","article-title":"Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older","volume":"58","author":"Boonen","year":"2010","journal-title":"J. Am. Geriatr. Soc."},{"issue":"6","key":"10.1016\/j.bone.2020.115330_bb0190","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/joim.12678","article-title":"Hip fracture risk and safety with alendronate treatment in the oldest-old","volume":"282","author":"Axelsson","year":"2017","journal-title":"J. Intern. Med."},{"issue":"10117","key":"10.1016\/j.bone.2020.115330_bb0195","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bone.2020.115330_bb0200","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115330_bb0205","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115330_bb0210","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115330_bb0215","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2020.115330_bb0220","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2020.115330_bb0225","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115330_bb0230","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bone.2020.115330_bb0235","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115330_bb0240","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two hyears of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior anti-resorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2020.115330_bb0245","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.bone.2020.115330_bb0250","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","volume":"93","author":"Miller","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10102","key":"10.1016\/j.bone.2020.115330_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bone.2020.115330_bb0260","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bone.2020.115330_bb0265","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2020.115330_bb0270","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115330_bb0275","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2020.115330_bb0280","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","article-title":"Bone loss after romosozumab\/denosumab: effects of bisphosphonates","volume":"103","author":"Horne","year":"2018","journal-title":"Calcif. Tissue Int."},{"issue":"12","key":"10.1016\/j.bone.2020.115330_bb0285","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A Prospective 2-Year Clinical Trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"9671","key":"10.1016\/j.bone.2020.115330_bb0290","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bone.2020.115330_bb0295","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1210\/jc.2012-2804","article-title":"Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation","volume":"97","author":"Shane","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2020.115330_bb0300","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2020.115330_bb0305","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1210\/er.2018-00001","article-title":"Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management","volume":"40","author":"Black","year":"2019","journal-title":"Endocr. Rev."},{"issue":"3","key":"10.1016\/j.bone.2020.115330_bb0310","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos. Int."},{"issue":"5","key":"10.1016\/j.bone.2020.115330_bb0315","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S8756-3282(98)00044-1","article-title":"Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment","volume":"22","author":"Ravn","year":"1998","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.bone.2020.115330_bb0320","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115330_bb0325","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.bone.2020.115330_bb0330","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115330_bb0335","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"36","key":"10.1016\/j.bone.2020.115330_bb0340","doi-asserted-by":"crossref","first-page":"E1130","DOI":"10.1503\/cmaj.161207","article-title":"Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial","volume":"189","author":"Grey","year":"2017","journal-title":"CMAJ"},{"issue":"6","key":"10.1016\/j.bone.2020.115330_bb0345","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1210\/jc.2012-1424","article-title":"Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men","volume":"97","author":"Bolland","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bone.2020.115330_bb0350","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/jbmr.3712","article-title":"Effects of intravenous zoledronate on bone turnover and bone density persist for at least 11 years in HIV-infected men","volume":"34","author":"Bolland","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115330_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2011.03.128","article-title":"Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 mg","volume":"48","author":"Black","year":"2011","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.bone.2020.115330_bb0365","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.clinthera.2019.05.001","article-title":"Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review","volume":"41","author":"Fardellone","year":"2019","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.bone.2020.115330_bb0370","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11657-017-0316-5","article-title":"Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States","volume":"12","author":"Durden","year":"2017","journal-title":"Arch. Osteoporos."},{"issue":"2","key":"10.1016\/j.bone.2020.115330_bb0375","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00198-014-2903-2","article-title":"Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Li","year":"2015","journal-title":"Osteoporos. Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:47:01Z","timestamp":1757612821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220301101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":74,"alternative-id":["S8756328220301101"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115330","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical guidance for the use of bisphosphonates in osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115330"}}